These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19327331)

  • 1. Safety of drotrecogin alfa (activated) in severe sepsis: data from adult clinical trials and observational studies.
    Woodward B; Cartwright M
    J Crit Care; 2009 Dec; 24(4):595-602. PubMed ID: 19327331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
    Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).
    Short MA; Schlichting D; Qualy RL
    Curr Med Res Opin; 2006 Dec; 22(12):2525-40. PubMed ID: 17265595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
    Vincent JL; Nadel S; Kutsogiannis DJ; Gibney RT; Yan SB; Wyss VL; Bailey JE; Mitchell CL; Sarwat S; Shinall SM; Janes JM
    Crit Care; 2005 Aug; 9(4):R331-43. PubMed ID: 16137345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
    Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
    N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
    De Backer D
    Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
    Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
    Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.
    Dhainaut JF; Yan SB; Joyce DE; Pettilä V; Basson B; Brandt JT; Sundin DP; Levi M
    J Thromb Haemost; 2004 Nov; 2(11):1924-33. PubMed ID: 15550023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
    Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
    Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.
    Sashegyi A; Trzaskoma BL; Nelson DR; Williams MD; Macias W
    Curr Med Res Opin; 2006 May; 22(5):1001-12. PubMed ID: 16709322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
    Dhainaut JF;
    Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
    Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
    J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
    Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
    Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
    Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
    Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials in severe sepsis with drotrecogin alfa (activated).
    Laterre PF
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S5. PubMed ID: 18269692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.